Oncology biotech Monopar Therapeutics files for a $40 million IPO
Monopar Therapeutics, a Phase 3 biotech developing therapies for cancer and the side effects of chemo, filed on Thursday with the SEC to raise up to $40 million in an initial public offering.
Monopar Therapeutics has three candidates in its pipeline. Its lead product candidate, Validive, is designed to reduce the incidence and effects of severe oral mucositis in patients undergoing chemoradiotherapy for oropharyngeal cancer. The company intends to begin a Phase 3 clinical trial for Validive in the 4Q19.
The Wilmette, IL-based company was founded in 2014 and plans to list on the Nasdaq under the symbol MNPR. JonesTrading is the sole bookrunner on the deal. No pricing terms were disclosed.
The article Oncology biotech Monopar Therapeutics files for a $40 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.